A new study demonstrates that anti-nephrin autoantibodies are not merely markers but also actively contribute to the pathogenesis of minimal change disease and primary focal segmental glomerulosclerosis. This insight not only provides a non-invasive diagnostic alternative to kidney biopsies, but also suggests potential for novel targeted therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Iijima, K. et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384, 1273–1281 (2014).
Watts, A. J. B. et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J. Am. Soc. Nephrol. 33, 238–252 (2022).
Takeuchi, K. et al. New anti-nephrin antibody mediated podocyte injury model using a C57BL/6 mouse strain. Nephron 138, 71–87 (2018).
Hengel, F. E. et al. Autoantibodies targeting nephrin in podocytopathies. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2314471 (2024).
Zhang, Y. M. et al. Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 11, 1582–1589 (2016).
Pedchenko, V. et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N. Engl. J. Med. 363, 343–354 (2010).
Uhlin, F. et al. Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study. J. Am. Soc. Nephrol. 33, 829–838 (2022).
Beck, L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11–21 (2009).
Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36–46 (2019).
Haddad, G. et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J. Clin. Invest. 131, e140453 (2021).
Acknowledgements
The authors thank Huang Kuang for creating the original artwork.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Cui, Z., Zhao, Mh. Anti-nephrin autoantibodies: a paradigm shift in podocytopathies. Nat Rev Nephrol (2024). https://doi.org/10.1038/s41581-024-00873-7
Published:
DOI: https://doi.org/10.1038/s41581-024-00873-7
